Veradermics scores another late-stage trial win for its hair loss therapy
FROM THE WIRE · SEEKINGALPHA.COM
Veradermics (MANE [https://seekingalpha.com/symbol/MANE]) gained in early premarket trading on Monday after announcing that another late-stage trial for its lead asset, VDPHL01, met all primary and secondary endpoints in patients with pattern hair loss, also known as…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive phase 3 data on the lead product can move the stock of a small biotech.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Phase 3 study '304 of VDPHL01 met all primary and secondary endpoints.
- 02The study enrolled 536 subjects with mild-to-moderate pattern hair loss.
- 03The stock gained in early premarket trading on Monday.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets